Trial Profile
A Human Physiologic Study to Evaluate the Renal and Neurohumoral Effects of Dual NPR-A and NPR-B Activation With a Novel Chimeric Natriuretic Peptide (CD-NP)in Subjects With Stable Chronic Heart Failure and Moderate Renal Dysfunction
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Cenderitide (Primary) ; Nesiritide
- Indications Heart failure
- Focus Pharmacodynamics
- 15 Nov 2013 Planned initiation date changed from 1 May 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
- 05 Jun 2013 Planned end date changed from 1 Mar 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov.
- 05 Jun 2013 Planned number of patients changed from 42 to 28 as reported by ClinicalTrials.gov.